Download full report with analyst certification and important disclosures
Feb 29 2024, 07:10 GMT
CVS Group
H1 2024 results reflect another period of good growth
- Sectors : Pharma and healthcare
- Companies : CVS Group
DAVY VIEW
Following the trading statement on January 25th, CVS has reported interim results to December 31st that reflect strong like-for-like top-line growth and an EBITDA margin of 19.1%, both of which are in its target range. Overall results are broadly as expected, and we are leaving our forecasts unchanged.
